|
| Press Releases |
|
 |
|
| Tuesday, July 4, 2017 |
|
|
Wellness Open Living Labs. LLC, Co-Founded by Eisai and Osaka City University Conclude Basic Collaboration Agreement Aimed at Solving Health Problems |
| Eisai Co., Ltd. announced today that Wellness Open Living Labs. LLC, co-founded by Eisai, and Osaka City University have concluded a basic collaboration agreement aimed at solving health science-related problems, such as dementia, and extending healthy life expectancy. more info >> |
|
| Wednesday, June 28, 2017 |
|
|
Eisai Listed for 16th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 16th consecutive year since its initial inclusion in 2002. more info >> |
|
| Tuesday, June 27, 2017 |
|
|
Eisai Temporarily Withdraws New Drug Application for Anticancer Agent Halaven in China |
| Eisai Co., Ltd. announced today that, in alignment with Chinese regulations, it has temporarily withdrawn its new drug application for anticancer agent eribulin mesylate (Brand name: Halaven) in China in order to submit additional documentation. more info >> |
|
| Friday, June 23, 2017 |
|
|
Eisai Submits Application for Additional Indication of Anticancer Agent Lenvima for Hepatocellular Carcinoma in Japan |
| Eisai Co., Ltd. announced today that it has submitted an application for an additional indication of its in-house discovered and developed anticancer agent Lenvima (generic name: lenvatinib mesylate) for the treatment of hepatocellular carcinoma (HCC) in Japan, the first in the world. more info >> |
|
|
Cardiovascular Outcomes Trial of Anti-Obesity Agent Lorcaserin to Continue Based on Recommendation of Independent Data Monitoring Committee After Completion of Interim Safety Analysis |
| Eisai Co., Ltd. has announced that it has received a recommendation from an independent Data Monitoring Committee to continue the ongoing Cardiovascular Outcomes Trial of lorcaserin hydrochloride after the completion of a pre-specified interim safety analysis, evaluating the incidence of Major Adverse Cardiovascular Events (MACE), defined as cardiovascular death, myocardial infarction or stroke. more info >> |
|
| Thursday, June 8, 2017 |
|
|
Launch of Pain Treatment Lyrica OD Tablet Formulation in Japan |
| Pfizer Japan Inc. and Eisai Co., Ltd. have announced that Lyrica OD Tablets 25mg, 75mg, 150mg (OD tablet: orally disintegrating tablet), a new formulation following pain treatment Lyrica Capsules (pregabalin). more info >> |
|
| Monday, June 5, 2017 |
|
|
Eisai to Present Results of Phase III Trial of Lenvima (Lenvatinib) as First-Line Treatment for Unresectable Hepatocellular Carcinoma in Oral Session at 53rd ASCO Annual Meeting |
| Eisai Co., Ltd. announced today that the results of a Phase III trial (Study 304) of its in-house discovered and developed anticancer agent lenvatinib mesylate against the comparator sorafenib as first-line treatment for unresectable hepatocellular carcinoma, will be orally presented during the 53rd Annual Meeting of ASCO. more info >> |
|
|
Eisai to Present Results of Phase Ib/II Study of Anticancer Agent Lenvima (Lenvatinib) in Combination With Anti-PD-1 Antibody Pembrolizumab |
| Eisai Co., Ltd. announced the first results for metastatic endometrial carcinoma obtained from a Phase Ib/II study (Study 111) of its in-house developed multi-kinase inhibitor lenvatinib mesylate in combination with the MSD anti-PD-1 antibody pembrolizumab (brand name: KEYTRUDA), during a presentation at the 53rd Annual Meeting of ASCO. more info >> |
|
| Thursday, June 1, 2017 |
|
|
Eisai Commits Funding to the 2nd Phase of Global Health Innovative Technology Fund Activities |
| Eisai Co., Ltd. has announced that it will grant a total of 500 million yen to the Global Health Innovative Technology Fund (GHIT Fund) to fund the second phase of its activities, which will take place in the five-year period from FY 2018 to FY 2022. more info >> |
|
| Wednesday, May 31, 2017 |
|
|
Eisai Enters Into a New Joint Research Agreement With the Broad Institute to Develop an Antimalarial Medicine |
| Eisai Co., Ltd. announced today that it has entered into a new joint research agreement with the Broad Institute, a collaborative research institute which includes researchers from the Massachusetts Institute of Technology and Harvard University to develop a new antimalarial medicine based on antimalarial drug targets the team identified last year. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Cryofocus Medtech: Steady Increase in Revenue and Gross Profit with Solid R&D Expenditures in 2024
Apr 1, 2025 00:42 HKT/SGT
|
|
|
AI Paradox in QA: Twice as Many Testers Fear Job Loss, But Adoption Keeps Climbing 
Mar 31, 2025 23:00 HKT/SGT
|
|
|
Dubai AI Festival returns for highly anticipated second edition as part of the inaugural Dubai AI Week
Mar 31, 2025 21:34 HKT/SGT
|
|
|
Huatai Securities Announces Dividend of RMB 3.7 per 10 Shares Following Record 2024 Performance
Mar 31, 2025 21:33 HKT/SGT
|
|
|
GF Securities Announces its 2024 Interim Results
Mar 31, 2025 21:33 HKT/SGT
|
|
|
Transforming Customer Experiences: Insights from Team Marksmen's CX Transformation Conclave
Mar 31, 2025 21:30 HKT/SGT
|
|
|
Vibe Marketing Tech Fest 2025 Will Focus on Convergence and Conversions
Mar 31, 2025 21:26 HKT/SGT
|
|
|
Local designer brands featured at 'Fashion Hong Kong Pop-up Salon' in Milan
Mar 31, 2025 21:20 HKT/SGT
|
|
|
Huatai Securities Reports Record 2024 Earnings and Advancement in Internationalization
Mar 31, 2025 21:18 HKT/SGT
|
|
|
Asiaray Achieves Net Profit Turnaround of RMB10.4 Million in 2024
Mar 31, 2025 16:52 HKT/SGT
|
|
|
Wuling Motors (00305.HK) Achieves a Surge of 115.6% in Net Profit Attributable to Shareholders for 2024
Mar 31, 2025 16:30 HKT/SGT
|
|
|
Fosun's Core Businesses Stay Firm Despite One-off Non-cash Loss
Mar 31, 2025 16:05 HKT/SGT
|
|
|
Five NTT Group Companies and Biome Inc. Start Joint Development of Large-scale Estimation Technology for Vegetation and Organisms using Satellite Image Data
Mar 31, 2025 15:43 JST
|
|
|
Yunkang's Revenue Proportion from Joint Construction Business for Medical Institution Alliances and Special Testing Items Continue to Grow in 2024
Mar 31, 2025 14:31 HKT/SGT
|
|
|
Avantor Recognized with Two Prestigious Awards at Asia-Pacific Biopharma Excellence Awards 2025
Mar 31, 2025 11:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
